Living with Eczema?
Topical treatments for Atopic Dermatitis (Eczema) don’t work for everyone.
If you’ve been diagnosed with eczema and topical remedies haven’t succeeded , you could be a fit for an upcoming study testing a new investigational treatment.
Interested? Fill out the survey below, and if you’re a fit we’ll be in touch about next steps.
See if you qualify
Fill out the form below to see if you meet the basic study requirements. You are under no legal obligation to enter information you are unwilling to provide. Your information will be used for study purposes only and will not be sold.
Why should I participate?
What would I have to do?
Frequently Asked Questions
This study is designed to help people with eczema by testing a novel investigational treatment option. The treatment is designed to help reduce inflammation and itchiness.
The investigational product is an injection designed to help reduce skin inflammation and rapidly reduce itching by targeting two key disease pathways at the same time.
Numab Therapeutics AG, a Switzerland-based Biotechnology company, is sponsoring the study.
You can receive compensation at the end of each study visit, totaling $1,995 at minimum by the end, if you attend each visit. Different locations have different compensation amounts, so please check with your study site for details.
There are 15 in-person visits, and 2 phone calls.
There are two 8-hour visits, and two 4-hour visits. However, most of that time is idle, so you’ll be able to work remotely, read, or just hang out at the study location.
The other 11 in-person visits are much shorter, likely under an hour, similar to a standard doctor’s checkup.
The study will last about 16 weeks from start to finish.